Navigation Links
NeoStem Vice President Will Speak on VSELs and Emerging Stem Cell Technologies at Age Management Medicine Conference
Date:9/9/2009

NEW YORK, Sept. 9 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today that Alan Harris, M.D., Ph.D., the Company's Vice President of Drug Development and Regulatory Affairs, will speak at a conference on Clinical Applications for Age Management Medicine, taking place in Las Vegas, November 5-8, 2009.

Dr. Harris's presentation will take place during a special pre-conference session on November 5, 2009, focused on "Regenerative Medicine: From Autologous Platelet Derived Growth Factors (PRP) to Stem Cells." The subject of his talk is "The Apheresis Product: A Rich Source of Pluripotent VSELs, Stem Cells and Progenitor Cells for Autologous Banking and Cellular Therapies."

Apheresis utilizes a minimally invasive procedure that members of NeoStem's collection network employ to collect stem cells from peripheral blood to store, using NeoStem's proprietary cryogenic technology, for the donor's personal use in time of medical need. NeoStem also holds a worldwide exclusive license to VSEL (Very Small Embryonic-Like) Cell Technology, and is supporting research programs at the University of Louisville as well as engaging in its own research and development activities. As Vice President of Drug Development and Regulatory Affairs, Dr. Harris oversees the Company's progress in these cutting edge arenas.

The Las Vegas events are organized by the Age Management Medicine Group (AMMG), dedicated to educating physicians and healthcare professionals on this growing medical specialty, age management medicine, through evidence-based scientific medical education conferences, workshops, seminars, publications and Web media. The Group, now in its fifth year, consists of leading industry healthcare professionals, physicians, practitioners, researchers, medical associations and providers of products and services. Attending the conference will be physicians, researchers, and health professionals, including dentists, chiropractors, nurses, physician assistants, nurse practitioners, pharmacists, psychologists and medical students.

Age management medicine is a proactive, preventive approach focused on preservation of optimum human function and quality of life, making every effort to modulate the process of aging prior to the onset of degenerative aging. The basic tenets of age management medicine are patient evaluation through extensive medical history, lifestyle assessment, physical examination and laboratory evaluation to establish personalized proactive treatment plans consisting of proper diet, exercise, stress management and appropriate medical interventions.

About NeoStem, Inc.

NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration. In 2009, the Company began to expand its operations into China in connection with the development of therapeutic adult stem cell technologies and is seeking to generate revenues through its regenerative medicine programs and technologies in China. For more information, please visit: www.neostem.com.

www.neostem.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

    CONTACT:
    NeoStem, Inc.
    Robin Smith, Chief Executive Officer
    T: 212-584-4180
    E: rsmith@neostem.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NeoStem to Present at Rodman & Renshaws 11th Annual Healthcare Conference
2. NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs
3. NeoStem Signs Agreement for Ceres Living, Inc. to Market Innovative Nutritional Supplement Designed to Optimize Stem Cell Functions
4. NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey
5. Suzanne Somers Appears on CNBCs Conversations with Michael Eisner and Discusses NeoStems Adult Stem Cell Collection Program
6. NeoStem Signs Definitive Agreement to Acquire Controlling Interest in a Leading Chinese Pharmaceutical Company
7. NeoStem, Inc. Comments on Recent Selling Pressure
8. NeoStem Signs Stem Cell Collection Agreement With University of Louisville Hospital
9. New Report to President and Congress Addresses Serious Oversights in National Health Care Debate
10. New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary, Helsinn Therapeutics (U.S.) Inc.
11. Pelosi, Reid Remarks at Press Availability Following Meeting With President Obama
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... The American Board of Family Medicine's (ABFM) Board of Directors ... Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in ... retirement at the end of 2018. Upon assuming the role of President and CEO ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: